Search for: "Sanofi"
Results 41 - 60
of 1,186
Sorted by Relevance
|
Sort by Date
16 Feb 2011, 12:00 am
The deal ends months of haggling after Sanofi-Aventis unsuccessfully sought to acquire Genzyme for $18.5 billion. [read post]
24 Jan 2011, 2:41 am
Sanofi-Aventis has extended its $69-a-share tender offer for all outstanding Genzyme common stock to Feb. 15. [read post]
8 Oct 2010, 6:49 am
The battle between Sanofi-Aventis and Genzyme is quickly becoming a war of words. [read post]
14 Jan 2011, 5:52 am
Le Figaro reports that Sanofi-Aventis is prepared to bid as much as $76 a share for Genzyme -- a big increase from its original $69 a share offer. [read post]
9 Feb 2011, 10:20 am
Viehbacher, chief executive of Sanofi-Aventis, cites "good progress" in talks, but says that due diligence is taking time. [read post]
4 Apr 2011, 6:12 am
Sanofi-Aventis says it has wrapped up its exchange offer for all Genzyme shares, an offer that expired just before midnight on Friday. [read post]
29 Sep 2010, 3:11 am
Sanofi-Aventis is weighing whether to make a sweetened takeover offer for Genzyme as soon as next week, people with knowledge of the matter told Bloomberg News. [read post]
13 Dec 2010, 1:11 am
Sanofi Aventis says its $69-a-share bid for Genzyme will remain open until Jan. 21, in a move that will keep the proposed deal alive. [read post]
27 Mar 2023, 1:15 pm
Sanofi, a case that even Sanofi’s counsel agreed could effectively wipe out patents involving genus claims if the Court sides with Sanofi, or—as counsel for Sanofi and the Solicitor General’s Office suggested the Court could do—if it were to dismiss the case as improvidently granted. [read post]
27 Mar 2023, 1:15 pm
Sanofi, a case that even Sanofi’s counsel agreed could effectively wipe out patents involving genus claims if the Court sides with Sanofi, or—as counsel for Sanofi and the Solicitor General’s Office suggested the Court could do—if it were to dismiss the case as improvidently granted. [read post]
21 Feb 2021, 9:59 pm
Sanofi that brought clarity to how the Court (and U.S. [read post]
12 Jan 2023, 10:46 am
The post Sanofi CEO: We Don’t Have A Leaky Bathtub appeared first on Above the Law. [read post]
27 Jul 2010, 9:56 pm
Sanofi-Aventis, et al. v. [read post]
28 Oct 2010, 4:38 am
The chief executive of Sanofi-Aventis reiterated his belief that French company's $18.5 billion hostile bid for Genzyme represented good value for the U.S. biotechnology firm, saying: "Nothing in what Genzyme has said in recent weeks would cause us to change our offer. [read post]
1 Dec 2010, 11:40 am
"A contingent value right would be a way to bridge a gap when different parties have different ideas on valuations," Sanofi Chief Financial Officer Jerome Contamine told Reuters on Wednesday. [read post]
7 Jan 2010, 1:47 pm
Sanofi, which over the years occupied a major share in the branded insomnia market by its Ambien Franchise, was counting high on Eplivanserin, [read post]
4 Nov 2022, 3:49 pm
Sanofi, and patent enablement appeared first on PatentAssociate.com. [read post]
16 Sep 2013, 4:00 am
Sanofi 2008 SCC 61 (“Sanofi SCC”) questions. [read post]
28 Aug 2012, 2:36 pm
Federal securities regulators charged eight people in Georgia with insider trading on Tuesday, saying they bought stock in a company ahead of a merger announcement after one of them learned about a pending acquisition by Sanofi-Aventis. [read post]
29 Jul 2010, 4:28 am
Sanofi-Aventis, the French pharmaceutical company considering an $18.6 billion bid for the U.S. biotechnology firm Genzyme, said profits jumped in the second quarter due to strong sales of its diabetes drugs and the weaker euro. [read post]
